MOSCOW (MRC) -- German conglomerate Bayer AG said its third-quarter net income increased to EUR999 mln from EUR826 mln in the previous year, said the company in its press release.
Earnings per share were EUR1.21, compared to EUR1.00 last year. Core earnings per share were EUR1.69, while it totaled EUR1.32 last year.
Sales climbed 10.7 percent to EUR11.036 bn from EUR9.967 bn in the prior year.
For full year 2015, Bayer continues to target a high-teens percentage increase in core earnings per share and expects positive currency effects of now around 4 percent, compared to around 5 percent expectation previously.
Bayer continues to predict that group sales will rise by a low single-digit percentage.
The Bayer Group now expects positive currency effects to raise sales by 6 percent, compared to the previous expectation of 7 percent. The firm plans sales in the region of EUR46 bn, compared to the previous estimate of EUR47 bn.
As MRC informed earlier, Bayer AG in the earlt September moved a step closer to floating its EUR11 billion (USD12.3 billion) specialty chemicals business by "legally and economically" separating the unit, now named Covestro AG.
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion.
MRC